INTRODUCTION AND OBJECTIVES: Currently bariatric surgery is the most effective treatment for significant and sustained weight loss. Erectile and endothelial dysfunctions may share some common metabolic and vascular pathways that may be influenced by weightloss. The aim of this study is to assess the effect of surgically induced weight loss on obese men with sexual dysfunction undergoing laparoscopic sleeve gastrectomy (LSG). We also aimed to analyse the proposed underlying mechanism associated with change in erectile function after weight loss by LSG.
INTRODUCTION AND OBJECTIVES: Currently bariatric surgery is the most effective treatment for significant and sustained weight loss. Erectile and endothelial dysfunctions may share some common metabolic and vascular pathways that may be influenced by weightloss. The aim of this study is to assess the effect of surgically induced weight loss on obese men with sexual dysfunction undergoing laparoscopic sleeve gastrectomy (LSG) . We also aimed to analyse the proposed underlying mechanism associated with change in erectile function after weight loss by LSG.
METHODS: Eighty two consecutive obese men who underwent a laparoscopic sleeve gastrectomy were followed for 12 months. All operations were performed by the same surgeon at a single institution. Patients were examined both before and after 12 months of LSG for biochemical tests; total serum cholesterol, triglyceride, C-reactive protein (CRP), interleukin-6 (IL-6) and endothelial nitric oxide synthase (eNOS) and for erectile function tests; International index of erectile function (IIEF) scores.
RESULTS: Eighty two men (mean age 39AE14.6years, range 24e62; mean BMI 41.2AE 4.8kg/m2) completed all pre-and postoperative questionnaires and biochemical tests. At 12 months the mean weight loss was 34.8?kg and the mean BMI decrease was 8.6?kg/m2. Preoperatively, 67 (77%) men (mean age 40AE 12.9 mean, BMI 42.2AE 5 kg/m2) were sexually active. Erectile function was significantly improved (p¼0.02). Men had a significant decrease in serum cholesterol and triglyceride levels. NOS activity showed a significant increase (P<0.02). In addition, our patients showed a statistically significant decrease in IL-6 levels and CRP compared with preoperative period (P<0.03 and P<0.01 respectively).
CONCLUSIONS: A significant improvement of erectile function was documented among obese young men undergoing bariatric surgery. This improvement was documented both clinically by improvement in IIEF score postoperatively and biochemically through reduction of hyperlipidemia and amelioration of both endothelial function and inflammatory cytokines.
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MP81-07 PENILE CARCINOMA: GENETICALLY ENGINEERED MODELS FOR NOVEL THERAPEUTICS IDENTIFICATION
Ahmed Sarhan*, Xiaoying Shang, Pherose Tamboli, Priya Rao, Curtis Pettaway, Alan Wang, Ronald DePinho, Xin Lu, Houston, TX INTRODUCTION AND OBJECTIVES: Penile cancer is rare but fatal malignant disease. The predominant histologic type of penile cancer is squamous cell carcinoma. The molecular mechanism of penile cancer has not been extensively studied thus far and remain poorly understood. We present the first genetically engineered penile cancer model in mice that represents a model for studying molecular mechanisms and pathway alterations in penile cancer pathogenesis METHODS: Two transgenic models that develop penile cancer through tissue-specific deletion of tumor suppressor genes were generated in a background nearly congenic to C57BL/6: deletion of smad4;Apc (model 1) and deletion of smad4;Apc; Pten (model 2). Penile prolapse was the phenotype of penile cancer formation. Tumor histology was confirmed by two pathologists (P.T., P.R.). Established penile tumors were harvested for RNAseq, reverse phase protein array (RPPA) and mass cytometry (CyTOF) for analyses if transcriptome, targeted proteome and immunophenotyping, respectively. In vivo treatment of mouse primary penile tumors was performed in 6 mice/ group using cisplatin chemotherapy RESULTS: Smad4; Apc mice developed primary penile tumors at 18-20 weeks of age, whereas Smad4; Apc; Pten mice develop tumors at 8-10 weeks. The tumors resembled penile squamous carcinoma by pathologic confirmation. In vivo treatment of mice with cisplatin revealed that that Pten loss could mediate tumor resistance to cisplatin treatment. CyTOF analysis showed a strong inflammatory phenotype of the tumors with massive infiltration of CD11b+ Gr1+ myeloid cells. Transcriptomic analysis indicates that COX-2 may be the master regulator of the inflammatory phenotype. RPPA analysis showed a number of highly regulated proteins and pathways in Smad4;Apc tumors compared with normal penis. Based on RPPA result, we are currently testing sensitivities of isolated penile cancer cell lines to a panel of 50 drugs, targeting molecules involved in pathways such as PI3K/AKT/mTOR, HER2/EGFR, SRC, JAK, STAT3, Bcl-XL, etc. We have also developed 4 penile cancer PDX models, and isolated penile cancer cell lines that grow squamous cell carcinoma in SCID mice from 2 of the 4 models. The PDX and cell lines will help validate our findings from transgenic mouse models.
CONCLUSIONS: A genetically engineered penile cancer mouse model was developed exhibiting a histologic and molecular phenotype that resembles human penile cancer. This model may assist in studying the mechanisms of tumor pathogenesis, progression and novel therapeutic strategies METHODS: Patients and Methods: Results of two randomized, double-blind, double-dummy, placebo-controlled, multi-center, Phase III studies (ZA-304/305) to evaluate two doses of EC versus AndroGel (AG) 1.62% on TT, LH and FSH and sperm counts in overweight men 18-60 years of age with secondary hypogonadism. Subjects in this trial exhibited early morning serum TT levels in the low or low normal range (¼300 ng/dL; ¼10.1 nmol/L) and had low or normal LH (<9.04 IU/L) Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e1091
